<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30158287</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>30</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1549-490X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>The oncologist</Title>                <ISOAbbreviation>Oncologist</ISOAbbreviation>            </Journal>            <ArticleTitle>Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">theoncologist.2017-0623</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1634/theoncologist.2017-0623</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The clinical relevance of molecular biomarkers in oncology management has been recognized in breast and lung cancers. We evaluated a blood-based multigene assay for management of neuroendocrine tumors (NETs) in a real-world study (U.S. registry NCT02270567). Diagnostic accuracy and relationship to clinical disease status in two cohorts (treated and watch-and-wait) were evaluated.</AbstractText>                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Patients with NETs (<i>n</i> = 100) were followed for 6-12 months. Patients' primary tumors were gastroenteropancreatic (68%), lung 20%, and of unknown origin (12%). Characteristics included well-differentiated, low-grade tumors (97%), stage IV disease (96%); treatment with surgery (70%); and drug treatment (56%). NETest was measured at each visit and disease status determined by RECIST. Scores categorized as low (NETest 14%-40%) or high (≥80%) defined disease as stable or progressive. Multivariate analyses determined the strength of the association with progression-free survival (PFS).</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">NETest diagnostic accuracy was 96% and concordant (95%) with image-demonstrable disease. Scores were reproducible (97%) and concordant with clinical status (98%). The NETest was the only feature linked to PFS (odds ratio, 6.1; <i>p</i> &lt; .0001). High NETest correlated with progressive disease (81%; median PFS, 6 months), and low NETest correlated with stable disease (87%; median PFS, not reached). In the watch-and-wait cohort, low NETest was concordant with stable disease in 100% of patients, and high NETest was associated with management changes in 83% of patients. In the treated cohort, all low NETest patients (100%) remained stable. A high NETest was linked to intervention and treatment stabilization (100%). Use of NETest was associated with reduced imaging (biannual to annual) in 36%-38% of patients.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Blood NETest is an accurate diagnostic and can be of use in monitoring disease status and facilitating management change in both watch-and-wait and treatment cohorts.</AbstractText>                <AbstractText Label="IMPLICATIONS FOR PRACTICE" NlmCategory="CONCLUSIONS">A circulating multigene molecular biomarker to guide neuroendocrine tumor (NET) management has been developed because current biomarkers have limited clinical utility. NETest is diagnostic (96%) and in real time defines the disease status (&gt;95%) as stable or progressive. It is &gt;90% effective in guiding treatment decisions in conjunction with diagnostic imaging. Monitoring was effective in watch-and-wait or treatment groups. Low levels supported no management change and reduced the need for imaging. High levels indicated the need for management intervention. Real-time liquid biopsy assessment of NETs has clinical utility and can contribute additional value to patient management strategies and outcomes.</AbstractText>                <CopyrightInformation>© AlphaMed Press 2018.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Eric</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Rocky Mountain Cancer Center, Denver, Colorado, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paulson</LastName>                    <ForeName>Scott</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Texas Oncology - Baylor Charles A Sammons Cancer Center, Dallas, Texas, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gulati</LastName>                    <ForeName>Anthony</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Bennett Cancer Center, Stamford, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Freudman</LastName>                    <ForeName>Jon</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Freudman Healthcare Consulting, San Rafael, California, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Grosh</LastName>                    <ForeName>William</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Emily Couric Cancer Center, University of Virginia, Charlottesville, Virginia, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kafer</LastName>                    <ForeName>Sheldon</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Hartford Hospital, Hartford, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wickremesinghe</LastName>                    <ForeName>Prasana C</ForeName>                    <Initials>PC</Initials>                    <AffiliationInfo>                        <Affiliation>Richmond University Medical Center, Staten Island, New York, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Salem</LastName>                    <ForeName>Ronald R</ForeName>                    <Initials>RR</Initials>                    <AffiliationInfo>                        <Affiliation>Yale University School of Medicine, Department of Surgery, New Haven, Connecticut, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bodei</LastName>                    <ForeName>Lisa</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Memorial Sloan Kettering Cancer Center, New York, New York, USA bodeil@mskcc.org.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Oncologist</MedlineTA>            <NlmUniqueID>9607837</NlmUniqueID>            <ISSNLinking>1083-7159</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">Biomarker</Keyword>            <Keyword MajorTopicYN="Y">Carcinoid</Keyword>            <Keyword MajorTopicYN="Y">Liquid biopsy</Keyword>            <Keyword MajorTopicYN="Y">NET transcripts</Keyword>            <Keyword MajorTopicYN="Y">Neuroendocrine</Keyword>            <Keyword MajorTopicYN="Y">Registry</Keyword>        </KeywordList>        <CoiStatement>Disclosures of potential conflicts of interest may be found at the end of this article.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>11</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>04</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>31</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30158287</ArticleId>            <ArticleId IdType="pii">theoncologist.2017-0623</ArticleId>            <ArticleId IdType="doi">10.1634/theoncologist.2017-0623</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>